Therapeutics Company's CEO Announces Speech at Major Annual Kidney Conference
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Speak at the H.C. Wainwright 3rd Annual Kidney Conference.
Disclaimer: The information provided in this article is for informational purposes only and should not be construed as medical or financial advice. Please consult relevant professionals before making any decisions based on this content.
Real-time information is available daily at https://stockregion.net
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage specialty biopharmaceutical company dedicated to developing first-in-class drugs for treating renal and inflammatory diseases, has announced that its Co-Founder, Chairman, Chief Executive Officer, and President, Stephen C. Glover, will be a featured speaker at the H.C. Wainwright 3rd Annual Kidney Conference. This virtual event is scheduled to take place on July 15, 2024, from 10:30 – 11:00 AM EDT.
Overview of the Conference and Presentation
The H.C. Wainwright Annual Kidney Conference is an esteemed event that brings together medical professionals, researchers, and industry leaders to discuss advancements in kidney disease treatment and management. This year marks the third edition of the conference, reflecting its growing significance within the nephrology community.
Stephen C. Glover’s presentation will center on the unique mechanism of action and developmental progress of Cholesterol Efflux Mediator™ VAR 200, a promising candidate in ZyVersa’s pipeline aimed at addressing unmet medical needs in renal health.
Kidney disease is a pressing health issue affecting millions globally. According to statistics provided by Mr. Glover, approximately 37 million Americans suffer from chronic kidney disease (CKD). This condition often progresses to end-stage renal disease (ESRD), necessitating dialysis or a kidney transplant. The American Kidney Fund reveals that around 808,000 Americans live with kidney failure, with more than 557,000 undergoing dialysis. Around 250,000 individuals have received kidney transplants, while more than 93,000 are on the waiting list for a transplant.
The limited treatment options available for CKD and ESRD highlight the urgent need for innovative therapies. This is where ZyVersa Therapeutics aims to make a meaningful impact with its pipeline of first-in-class drugs.
Spotlight on Cholesterol Efflux Mediator™ VAR 200
Cholesterol Efflux Mediator™ VAR 200, also known as 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), is a phase 2 drug designed to mitigate renal lipid accumulation that can lead to kidney disease progression. VAR 200 works through both passive and active mechanisms to remove excess lipids from the kidneys, thereby protecting against structural damage and reducing proteinuria (protein excretion in urine). Preclinical studies conducted on animal models of various kidney diseases, including focal segmental glomerulosclerosis (FSGS), Alport syndrome, and diabetic kidney disease, have shown promising results. These studies indicate that VAR 200 effectively removes excess cholesterol and lipids from kidney podocytes, which are crucial cells in the kidney's filtration system. This lipid removal helps safeguard the structural integrity of the filtration system and reduces proteinuria, a common symptom of kidney disease.
The lead indication for VAR 200 is FSGS, an orphan kidney disease characterized by scarring (sclerosis) in the glomeruli—the tiny filtering units within the kidney. FSGS often leads to proteinuria and progressive loss of kidney function. Currently, treatment options for FSGS are limited, underlining the potential impact of VAR 200. Beyond FSGS, VAR 200 shows potential for treating other glomerular diseases, including Alport syndrome and diabetic kidney disease. Both conditions involve similar pathological processes related to lipid accumulation and structural damage within the kidneys. If successful in clinical trials, VAR 200 could offer a versatile therapeutic option for multiple kidney diseases.
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop first-in-class drugs targeting unmet medical needs in inflammatory and kidney diseases. The company's pipeline includes two primary candidates: Inflammasome ASC Inhibitor IC 100 and Cholesterol Efflux Mediator™ VAR 200. IC 100 is a highly differentiated monoclonal antibody targeting inflammasomes—complexes of proteins involved in the inflammatory response. The lead indication for IC 100 is obesity and its associated metabolic complications, which are linked to chronic inflammation. By inhibiting inflammasome activity, IC 100 aims to modulate the inflammatory response and address metabolic dysfunctions associated with obesity.
As previously discussed, VAR 200 is being developed to treat kidney diseases characterized by lipid accumulation and structural damage. Initially targeted at FSGS, VAR 200 has the potential to expand into other glomerular diseases, offering a "pipeline within a product" due to its versatile mechanism of action. ZyVersa estimates the total accessible market for its products to exceed $100 billion. This market potential, combined with the high unmet medical needs addressed by their drug candidates, positions ZyVersa as a key player in the biopharmaceutical landscape.
Stephen C. Glover’s upcoming presentation at the H.C. Wainwright 3rd Annual Kidney Conference underscores ZyVersa Therapeutics' commitment to advancing innovative treatments for kidney disease. With its promising candidate, Cholesterol Efflux Mediator™ VAR 200, the company aims to address the substantial unmet medical needs of patients with renal diseases such as FSGS, Alport syndrome, and diabetic kidney disease. As ZyVersa continues to push the boundaries of biopharmaceutical research, it holds the potential to bring new hope to millions of patients affected by these debilitating conditions.
For those interested in learning more about ZyVersa and its pioneering work, opportunities to schedule one-on-one meetings with Mr. Glover through the conference portal are available.
Disclaimer: The content of this article is intended for informational purposes only and does not constitute medical or financial advice. Always consult with a qualified professional before making decisions based on the information provided herein.
Real-time information is available daily at https://stockregion.net